According to foreign media reports, recently, France and Germany's drug regulatory department of a common diabetes drug, "pyrrole rosiglitazone," issued an injunction, alleged that the drug was found with the incidence of bladder cancer, there may be positive relationship.
Commonly used in clinical medicine "pyrrole rosiglitazone."
May increase the risk of bladder cancer
British pharmaceutical and healthcare products regulatory agencies (MHRA) recently found that taking two "Ai Extension" (Ike properly, Ai proper sugar, pyrrole rosiglitazone) diabetes patients suffering from bladder cancer, bladder cancer, although not directly confirm This may be drug-related diabetes, but the MHRA has to European health authorities issued a circular to alert potential drug risks.
"Ai Extension" (Ike properly, Ai proper sugar, pyrrole rosiglitazone) in 2000 by a Japanese company Takeda for patients with type 2 diabetes, hypoglycemic drugs, insulin sensitizers that can effectively alleviate the insulin resistance to control blood sugar levels in patients, known side effects include causing weight gain, fluid retention and heart failure, and so on. All along, the drug is Takeda's leading products, global sales are very impressive.
Early last year, the United Kingdom for 233 000 people in an epidemiological survey has found that taking "Ai extension" of the patients increased incidence of bladder cancer, the results for the United States made a rapid response, the United States Food and drug regulatory authorities actively started a medication review.
Part of the country has been disabled
Most were wait and see attitude
Last week, French drug safety agency announced the first clinical disabled "Ai Extension", but the reason has nothing to do and bladder cancer, but because studies have shown that taking the "Ai Extension" may increase the incidence of macrosomia. German health authorities have also disabled the drug.
UK MHRA officials said, although there are reports of 573 cases of the UK, "Ai Extension" adverse reactions found in two patients suffering from bladder cancer, but this does not mean that the drug is toxic.
The MHRA spokesman said: "Although there have been some drug adverse reactions that may exist, but now stopping the drug too early, we do not want to rush out of patients because of fear of drug, which is why we not declared out, but only to inform the European regulatory authorities to review the reason! "
According to reports, the European Medicines management reports for these countries are being evaluated to ensure it can continue to use the drug, will soon determine the final result.
Commonly used in clinical medicine "pyrrole rosiglitazone."
May increase the risk of bladder cancer
British pharmaceutical and healthcare products regulatory agencies (MHRA) recently found that taking two "Ai Extension" (Ike properly, Ai proper sugar, pyrrole rosiglitazone) diabetes patients suffering from bladder cancer, bladder cancer, although not directly confirm This may be drug-related diabetes, but the MHRA has to European health authorities issued a circular to alert potential drug risks.
"Ai Extension" (Ike properly, Ai proper sugar, pyrrole rosiglitazone) in 2000 by a Japanese company Takeda for patients with type 2 diabetes, hypoglycemic drugs, insulin sensitizers that can effectively alleviate the insulin resistance to control blood sugar levels in patients, known side effects include causing weight gain, fluid retention and heart failure, and so on. All along, the drug is Takeda's leading products, global sales are very impressive.
Early last year, the United Kingdom for 233 000 people in an epidemiological survey has found that taking "Ai extension" of the patients increased incidence of bladder cancer, the results for the United States made a rapid response, the United States Food and drug regulatory authorities actively started a medication review.
Part of the country has been disabled
Most were wait and see attitude
Last week, French drug safety agency announced the first clinical disabled "Ai Extension", but the reason has nothing to do and bladder cancer, but because studies have shown that taking the "Ai Extension" may increase the incidence of macrosomia. German health authorities have also disabled the drug.
UK MHRA officials said, although there are reports of 573 cases of the UK, "Ai Extension" adverse reactions found in two patients suffering from bladder cancer, but this does not mean that the drug is toxic.
The MHRA spokesman said: "Although there have been some drug adverse reactions that may exist, but now stopping the drug too early, we do not want to rush out of patients because of fear of drug, which is why we not declared out, but only to inform the European regulatory authorities to review the reason! "
According to reports, the European Medicines management reports for these countries are being evaluated to ensure it can continue to use the drug, will soon determine the final result.
No comments:
Post a Comment